This year’s first approved drugs, thrombocytopenic purpura antidiabetics
Although decided as ‘non-benefit’ due to unclear cost-effectiveness last year, treatments which will stably receive the benefit through reevaluation were revealed for this year.
According to the Drug Registration Division of the Health Insurance Review & Assessment Service, Kyowa Hakko Kirin Kor...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
